Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $1.2 million.

  • Entrada Therapeutics' Depreciation & Amortization (CF) rose 3333.33% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 2236.31%. This contributed to the annual value of $3.8 million for FY2024, which is 3375.57% up from last year.
  • Entrada Therapeutics' Depreciation & Amortization (CF) amounted to $1.2 million in Q3 2025, which was up 3333.33% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Depreciation & Amortization (CF) ranged from a high of $1.2 million in Q3 2025 and a low of $400000.0 during Q1 2022
  • Its 4-year average for Depreciation & Amortization (CF) is $777133.3, with a median of $800000.0 in 2023.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 7264.33% in 2024, then skyrocketed by 128.48% in 2025.
  • Quarter analysis of 4 years shows Entrada Therapeutics' Depreciation & Amortization (CF) stood at $500000.0 in 2022, then skyrocketed by 47.2% to $736000.0 in 2023, then soared by 35.87% to $1.0 million in 2024, then grew by 20.0% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $1.1 million for Q2 2025, and $946000.0 during Q1 2025.